Extended Data Fig. 7: HDAC inhibitors diminish TCR expression in T-cells.
From: Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics
a) Three measures of cell viability of Jurkat cells treated with panobinostat. b) Loss of CD3E expression in response to HDAC inhibitors. c) Loss of mRNA expression of several members of the TCR in response to vorinostat. d) Microscopic pictures of HDAC inhibitor-treated and CD3/CD28-activated CD8- and CD4- positive primary human T-cells (n = 1). e) Dose-dependent reduction of TCF7 protein expression in primary human T-cells (naïve only) in response to HDAC inhibitors. f) Dose-dependent reduction of GZMB protein expression in primary human T-cells (activated only).
